National organization for rare disorders, quantum of effectiveness evidence in fda's approval of orphan drugs: cataloguing FDA's flexibility in regulating therapies for persons with rare disorders [EB/OL]. (2011-10-11)[2011-12-08]. http://www.rarediseases.org/ docs/ policy/ NORDstudyofFDA...
The National Organization for Rare Disorders announced three new grant funding opportunities related to the following rare diseases: Arteriovenous Malformation, Levy-Yeboa Syndrome, and Megacystis Microcolon Intestinal Hypoperistalsis Syndrome.
The Relationship between Oral Health and Brain Function WATANABE Makoto 日本歯科医学会誌 = Journal of the Japanese Association for Dental Science : JJDS (28), 60-63, 2009-03-31Maud GancelWassilios MeissnerFrançois Tison日本歯科医学会誌...
EUROPLAN: a project to support the development of national plans on rare diseases in Europe. National Plans for Rare Diseases (RDs) are the common denominator of current public health policy concerns on RDs across the EU. With the aim of a better d... Taruscio,A E,Gentile,... - 《Pub...
The European Commission, recognizing that a number of healthcare and knowledge issues are common to all rare diseases in spite of the wide variety of their clinical manifestation, has recently initiated the promotion of national plans and comprehensive strategies for improving the provision of care ...
2. Enhanced coverage for rare diseases implemented for the first time. Orphan drugs, pharmaceuticals that remains commercially undeveloped owing to limited potential for profitability, remain a key focus in the 2023 NRDL revision. In the 2022 NRDL revision, the NSHA introduced a new po...
Meanwhile, 15 drugs that can treat 16 types of rare diseases have been included. There were no drugs for 10 of these rare diseases before the latest adjustment.
Instead, we will provide a translation of the Decision (sans the charts) and discuss three issues related to the Decision: the NPCSC’s involvement in this major policy decision; the swift and secretive way in which the Decision was adopted; and the Decision’s unusual makeup—i.e., its ...
CONCLUSION: Results of the present study will have implications for policy making; as they allow for understanding geographic distributions of the selected GI diseases, and identifying health disparities across provinces. 展开 关键词:Burden of illness Costs of disease Illness Burden ...
Neglected Diseases National Institutes of Health Announces New Program To Develop Therapeutics For Rare And Neglected DiseasesNational Institutes of Health Announces New Program To Develop Therapeutics For Rare And Neglected DiseasesGeoffrey Spencer